Glutathione: What the Oral, Intravenous and Topical Studies Report

By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 9 November 2026

ExaVeyra Sciences is a Miami-based B2B supplier of exosomes for topical aesthetic use to licensed clinics, and it works with a 503A compounding pharmacy that prepares formulations for licensed prescribers against individual prescriptions.

What this page covers, who can buy from ExaVeyra, and what is supplied
QuestionAnswer
What this page coversWhat the oral, intravenous and topical glutathione studies reported, and the FDA alert on endotoxin in a bulk glutathione powder.
Who can orderLicensed clinics and practitioners whose active professional license and NPI ExaVeyra has verified. Exosome orders also require a signed professional-use acknowledgment.
What ships, and howCompounded formulations are prepared and dispensed by our 503A pharmacy partner against a patient-specific prescription from the licensed prescriber and ship from the pharmacy. The pharmacy dispenses any controlled substance under its own DEA registration.

The glutathione evidence divides by route. Two randomized trials of oral glutathione in healthy adults reached opposite conclusions: Allen and Bradley reported no change in glutathione status after four weeks in 40 volunteers, while Richie and colleagues reported increased blood glutathione after six months in 54 adults that returned to baseline after a one-month washout.[1][2] One randomized split-face trial of a topical oxidized glutathione lotion in 30 women reported a lower melanin index than placebo at ten weeks.[3] Intravenous glutathione has no randomized skin trial indexed in PubMed; a 2018 dermatology review describes one small placebo-controlled intravenous skin study of doubtful design, and the controlled trials that PubMed does index were run in other settings, including a 21-person pilot in Parkinson disease.[4][5] FDA's compounding alerts of June 2019 and August 2026 describe endotoxin reactions in patients who received intravenous glutathione compounded from powder labeled for dietary supplement use.[6][7]

This page reports what each trial, review and FDA communication states, with the design and participant count of each study, and where glutathione sits in the 503A bulk drug substance record as of 8 November 2026.[8][9]

Glutathione is a tripeptide thiol that cells synthesize in two steps and recycle between reduced and oxidized forms

Glutathione is the tripeptide gamma-glutamyl-cysteinyl-glycine, present in all mammalian tissues as "the most abundant non-protein thiol that defends against oxidative stress", in the words of Lu's 2013 review.[10] Synthesis takes place in the cytosol in two ATP-dependent steps: glutamate cysteine ligase, the rate-limiting enzyme, joins glutamate and cysteine, and glutathione synthetase adds glycine; Lu identifies cysteine availability as a key determinant of the rate and names Nrf2 among the transcription factors regulating the synthetic genes.[10] The reduced form (GSH) is oxidized to glutathione disulfide (GSSG) in peroxidase reactions and recycled by GSSG reductase, and Lu describes the GSH to GSSG ratio as the main determinant of intracellular redox potential, a measure three of the oral trials below report.[10]

The glutathione transferases conjugate GSH to electrophilic xenobiotics; Allocati and colleagues describe this activity as playing "a critical role in cellular detoxification against xenobiotics and noxious compounds as well as against oxidative stress".[11] The skin hypothesis rests on melanin chemistry: Sonthalia, Daulatabad and Sarkar describe glutathione's reported effect on skin color as direct and indirect inhibition of tyrosinase and a switch from eumelanin to pheomelanin synthesis, and note that the molecule "is available in oral, parenteral and topical forms".[12]

What the oral trials in healthy adults report about body stores of glutathione

Allen and Bradley ran a randomized, double-blind, placebo-controlled trial of oral glutathione in 40 adult volunteers without acute or chronic disease for four weeks, measuring urinary oxidative stress markers and erythrocyte GSH, GSSG and their ratio.[1] The authors reported that "No significant changes were observed in biomarkers of oxidative stress, including glutathione status".[1]

Richie and colleagues then ran a six-month randomized, double-blind, placebo-controlled trial of a daily oral glutathione supplement at two dose levels in 54 non-smoking adults.[2] They reported that blood glutathione rose at one, three and six months in both groups; at six months the higher-dose group showed mean increases of 30 to 35 percent in erythrocytes, plasma and lymphocytes and 260 percent in exfoliated buccal cells, the whole blood GSSG to GSH ratio fell, natural killer cytotoxicity more than doubled in the higher-dose group at three months, and "levels returned to baseline after a 1-month washout period".[2]

Sinha and colleagues, from the same group, reported a one-month pilot of oral liposomal glutathione in 12 healthy adults with no placebo arm: glutathione rose in blood compartments within one to two weeks and immune markers increased.[13] The authors called the findings preliminary, noted the limited statistical power, and disclosed funding from the company that sells the product tested.[13] The systematic review by Dilokthornsakul and colleagues frames the question the oral trials leave open: "the clinical efficacy of glutathione in oral form is still questionable due to its limited absorption and bioavailability".[14]

What the oral skin studies report about melanin index, and what one of them reported about liver tests

Arjinpathana and Asawanonda randomized 60 otherwise healthy medical students in Bangkok to a daily oral glutathione capsule or placebo for four weeks and measured melanin index at six skin sites.[15] Melanin indices fell at all six sites in the glutathione group and exceeded placebo significantly at two, the right side of the face and the sun-exposed left forearm; the authors concluded that the effect appeared "in a small number of subjects. However, long-term safety has not been established and warrants more extensive clinical trials."[15]

Weschawalit and colleagues, from the same group, randomized sixty healthy volunteers to daily oral reduced glutathione, oral oxidized glutathione or placebo for twelve weeks, with blood drawn for safety monitoring.[16] Melanin index and ultraviolet spots tended to be lower than placebo in both glutathione arms, wrinkles were reduced at some sites in the reduced glutathione arm, and the authors reported no serious adverse effects; the full text records that two volunteers withdrew "due to elevation in liver function tests", a finding the abstract omits.[16]

The systematic review by Dilokthornsakul and colleagues searched five databases to October 2017 and found four clinical studies in healthy volunteers, three of them randomized.[14] It reported melanin index reductions at sun-exposed sites only, some nonserious adverse events, and that "Current evidence of the skin whitening effect of glutathione is still inconclusive due to the quality of included studies and inconsistent findings".[14]

What the one randomized topical trial reports, and who authored it

Watanabe and colleagues ran a randomized, double-blind, matched-pair, placebo-controlled trial in 30 healthy women aged 30 to 50 who applied an oxidized glutathione lotion to one side of the face and a placebo lotion to the other for ten weeks.[3] The melanin index was significantly lower on the treated side through week ten, the treated side later showed higher stratum corneum moisture and less wrinkle formation, and the authors reported "no marked adverse effects".[3] Three of the four authors list affiliations with the development center of the company that supplied the oxidized glutathione ingredient, and the trial was conducted at a contract research site in the Philippines.[3] Sonthalia, Jha and colleagues summarized the topical record in 2018 as "one trial involving the use of topical glutathione" reporting "appreciable but reversible results on skin tone".[4]

Intravenous glutathione has no randomized skin trial in PubMed and one disputed skin study

Randomized, placebo-controlled trials of intravenous glutathione indexed in PubMed come from vascular, cardiac and neurological settings, none of them in skin.[5][17][18] The neurological example is the 2009 pilot by Hauser and colleagues, which enrolled 21 participants with Parkinson disease and gave several infusions a week for four weeks.[5] The authors reported that glutathione "was well tolerated and there were no withdrawals because of adverse events in either group" and that there were no significant differences in Unified Parkinson's Disease Rating Scale scores.[5]

Sonthalia, Daulatabad and Sarkar wrote in 2016 that "Although the use of intravenous glutathione injections is popular, there is no evidence to prove its efficacy", and recorded that reported adverse effects led the Food and Drug Administration of the Philippines to issue a public warning against its use for skin lightening.[12] The 2018 review by Sonthalia, Jha and colleagues states that the intravenous evidence for skin lightening "is limited to a single study with a dubious study design and apparently flawed analysis of results", and identifies that study as a placebo-controlled trial of intravenous glutathione by Zubair and colleagues.[4] A 2025 narrative review by Alzahrani and colleagues reported that intravenous glutathione "is associated with serious safety concerns like anaphylaxis and hepatotoxicity".[19]

FDA's compounding alerts describe endotoxin reactions after intravenous glutathione made from dietary supplement grade powder

On 1 February 2019 FDA warned compounders not to use glutathione L-reduced powder distributed by a repackager named in the FDA alert to compound sterile injectable drugs, and on 7 June 2019 it published the investigation.[6] Seven patients in one outpatient clinic received intravenous infusions of compounded L-glutathione on 9 January 2019: "Within minutes of the infusion, the patients reportedly experienced symptoms of varying degrees, including nausea, vomiting, lightheadedness, chills, body aches and sneezing", and one developed low blood pressure and difficulty breathing and was transferred to a hospital.[6] A second report described a patient of a different pharmacy who "experienced sudden chills, fever and shaking" after an infusion in October 2018 and was admitted for a possible bloodstream infection.[6]

FDA's laboratory tested powder samples from the repackager and from the compounding pharmacy and found that all "were found to contain excessive bacterial endotoxin with some results as high as five times the appropriate limit" calculated from the dose the patients received.[6] The powder's label carried the statement "Caution: Dietary Supplement", and the foreign manufacturer confirmed that its glutathione "is only marketed in the U.S. for use in dietary supplements, and that the ingredient is not intended for use in sterile drugs".[6] FDA concluded that "compounders should ensure that all ingredients they use to produce sterile injectable drugs are manufactured under conditions and specifications appropriate for the intended route of administration", and that testing alone "should not be relied on to ensure drug quality".[6]

On 27 August 2026 FDA published a second alert.[7] The agency stated that it was "aware of reports of at least 30 patients who experienced adverse events following the administration of intravenous (IV) glutathione alone or in combination with other ingredients", that the glutathione had been compounded by different pharmacies which all obtained one lot from a single distributor named in the FDA alert, labeled as dietary supplement grade, and that two Texas pharmacies had conducted recalls for elevated endotoxin levels.[7] Reported events "included fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, with some resulting in hospitalizations", which FDA described as consistent with excessive endotoxin exposure.[7] The distributor told FDA on 20 August 2026 that it had warned its customers, and FDA stated that it "continues to receive reports of adverse events consistent with endotoxin exposure and is actively investigating".[7] As of 8 November 2026 the 2026 entry is the most recent item on FDA's Compounding Risk Alerts index.[20]

Glutathione sits in category 1 of the 503A bulk substance nominations, and the statute sets the sourcing conditions

Section 503A(b)(1)(A) permits compounding with bulk drug substances that comply with an applicable USP or NF monograph, are components of approved drugs, or "appear on a list developed by the Secretary through regulations", and requires that they "are manufactured by an establishment that is registered under section 360 of this title" and "are accompanied by valid certificates of analysis for each bulk drug substance".[21] FDA's compounding page restates these conditions and adds: "The agency urges compounders to know your bulks supplier."[8]

FDA's document of bulk drug substances nominated for the 503A list, updated 14 May 2026, places "Glutathione" in category 1, the substances "Under Evaluation" that were nominated with sufficient supporting information and do not appear on any other list.[9] Under FDA's interim policy the agency "does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met".[8] Glutathione does not appear in category 2, and no final rule placing it on or keeping it off the 503A bulks list had issued as of 8 November 2026.[8][9]

DateFDA actionWhat the record states
1 February 2019Warning to compounders on one repackager's L-glutathioneSeven patients at one clinic reacted within minutes of infusion; powder labeled Caution: Dietary Supplement
7 June 2019Compounding alert publishing the investigationFDA samples contained excessive endotoxin, some up to five times the appropriate limit
14 May 2026Bulk substances category document updatedGlutathione listed in category 1, under evaluation
27 August 2026Reminder on dietary supplement grade glutathioneAt least 30 patients with adverse events; one distributor lot; two Texas pharmacy recalls

Sourcing documents a practice can request for compounded glutathione

The human evidence for oral glutathione is small and inconsistent, the topical evidence is one trial authored mainly by the ingredient's manufacturer, and the intravenous evidence for skin rests on one disputed study, with controlled trials only in other populations and review-level reports of anaphylaxis and hepatotoxicity.[1][2][3][4][5][19] The harms FDA documented in the United States arose from bulk powder labeled as a dietary supplement ingredient that carried endotoxin inappropriate for intravenous use, and the documents a practice would hold follow from FDA's recommendations.[6][7]

  • The identity of the bulk glutathione source for each lot, with the upstream manufacturer named on the label and the certificate of analysis, as FDA asked suppliers in 2026.
  • A valid certificate of analysis for each bulk drug substance and confirmation that it was manufactured by an FDA-registered establishment, which section 503A(b)(1)(A) requires.[21]
  • Confirmation that the bulk substance is manufactured for the intended route of administration, the sourcing condition FDA stated in 2019 and repeated in 2026.

ExaVeyra supplies glutathione through a licensed 503A pharmacy partner on a patient-specific prescription, and the certificate of analysis for each lot is available on request. Whether glutathione suits a given patient, by which route, and with what monitoring are decisions for the prescribing practitioner, and our team can walk a practice through the sourcing documents listed above.

This article summarizes published studies and publicly available federal regulation for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.

Annotated References

Numbered in the order they are cited in the text. Each source is annotated with what it supports on this page; peer-reviewed articles are listed with journal, volume, issue and pages, and primary sources are regulations, agency documents, guidelines and position statements.

  1. 1.Peer-reviewedAllen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine. 2011;17(9):827-833. https://pubmed.ncbi.nlm.nih.gov/21875351/Annotation: Four-week randomized, double-blind, placebo-controlled trial in 40 healthy adults: no change in urinary F2-isoprostanes, 8-OHdG, or erythrocyte GSH, GSSG or their ratio.
  2. 2.Peer-reviewedRichie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015;54(2):251-263. https://pubmed.ncbi.nlm.nih.gov/24791752/Annotation: Six-month randomized, double-blind, placebo-controlled trial at two dose levels in 54 non-smoking adults: increases in blood compartment glutathione that reversed after a one-month washout, and increased natural killer cytotoxicity.
  3. 3.Peer-reviewedWatanabe F, Hashizume E, Chan GP, Kamimura A. Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women. Clinical, Cosmetic and Investigational Dermatology. 2014;7:267-274. https://pubmed.ncbi.nlm.nih.gov/25378941/Annotation: Ten-week randomized, double-blind split-face trial of a topical oxidized glutathione lotion in 30 healthy women: lower melanin index than placebo and no marked adverse effects; three authors affiliated with the ingredient supplier, trial run at a contract research site.
  4. 4.Peer-reviewedSonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatology Practical and Conceptual. 2018;8(1):15-21. https://pubmed.ncbi.nlm.nih.gov/29445569/Annotation: The 2018 assessment that intravenous evidence for skin lightening rests on a single study with a dubious design, and that the oral and topical trials reported reversible effects on skin tone.
  5. 5.Peer-reviewedHauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders. 2009;24(7):979-983. https://pubmed.ncbi.nlm.nih.gov/19230029/Annotation: A randomized, placebo-controlled pilot of intravenous glutathione in 21 participants with Parkinson disease: good tolerability, no significant difference on the rating scale.
  6. 6.RegulatoryFDA, FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables (Compounding Alert, June 7, 2019). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables
  7. 7.RegulatoryFDA, FDA reminds compounders not to use dietary supplement grade glutathione for injectables (August 27, 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
  8. 8.RegulatoryFDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  9. 9.RegulatoryFDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1, 2 and 3; updated May 14, 2026). Accessed 8 November 2026. https://www.fda.gov/media/94155/download?attachment
  10. 10.Peer-reviewedLu SC. Glutathione synthesis. Biochimica et Biophysica Acta. 2013;1830(5):3143-3153. https://pubmed.ncbi.nlm.nih.gov/22995213/Annotation: The two-step cytosolic synthesis of glutathione, the rate-limiting glutamate cysteine ligase, cysteine availability and Nrf2 regulation, and the GSH to GSSG redox pair.
  11. 11.Peer-reviewedAllocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018;7(1):8. https://pubmed.ncbi.nlm.nih.gov/29362397/Annotation: The glutathione transferase conjugation activity in cellular detoxification of xenobiotics, and its exploitation by tumor cells for drug resistance.
  12. 12.Peer-reviewedSonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian Journal of Dermatology, Venereology and Leprology. 2016;82(3):262-272. https://pubmed.ncbi.nlm.nih.gov/27088927/Annotation: The tyrosinase inhibition and eumelanin to pheomelanin mechanism, the statement that intravenous glutathione has no efficacy evidence, and the Philippine regulator's public warning.
  13. 13.Peer-reviewedSinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, Schell TD, Richie JP Jr. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition. 2018;72(1):105-111. https://pubmed.ncbi.nlm.nih.gov/28853742/Annotation: One-month open pilot of oral liposomal glutathione in 12 healthy adults: rises in blood compartment glutathione and immune markers, limited power, funded by the product's seller.
  14. 14.Peer-reviewedDilokthornsakul W, Dhippayom T, Dilokthornsakul P. The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. Journal of Cosmetic Dermatology. 2019;18(3):728-737. https://pubmed.ncbi.nlm.nih.gov/30895708/Annotation: Systematic review to October 2017 finding four clinical studies in healthy volunteers, inconclusive evidence on skin color, effects limited to sun-exposed sites, and nonserious adverse events.
  15. 15.Peer-reviewedArjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment. 2012;23(2):97-102. https://pubmed.ncbi.nlm.nih.gov/20524875/Annotation: Four-week randomized, double-blind, placebo-controlled trial in 60 healthy medical students: melanin index fell at all six sites, significantly against placebo at two, with long-term safety stated as not established.
  16. 16.Peer-reviewedWeschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clinical, Cosmetic and Investigational Dermatology. 2017;10:147-153. https://pubmed.ncbi.nlm.nih.gov/28490897/Annotation: Twelve-week three-arm randomized trial of oral reduced glutathione, oral oxidized glutathione or placebo in sixty healthy volunteers: melanin index tended lower, wrinkles reduced at some sites, and two withdrawals for elevated liver function tests in the full text.
  17. 17.Peer-reviewedArosio E, De Marchi S, Zannoni M, Prior M, Lechi A. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Mayo Clinic Proceedings. 2002;77(8):754-759. https://pubmed.ncbi.nlm.nih.gov/12173710/Annotation: Randomized, double-blind, placebo-controlled trial of intravenous glutathione twice daily for five days against saline in 40 patients with peripheral artery disease.
  18. 18.Peer-reviewedTanzilli G, Truscelli G, Arrivi A, Carnevale R, Placanica A, Viceconte N, Raparelli V, Mele R, Cammisotto V, Nocella C, Barillà F, Lucisano L, Pennacchi M, Granatelli A, Dominici M, Basili S, Gaudio C, Mangieri E. Glutathione infusion before primary percutaneous coronary intervention: a randomised controlled pilot study. BMJ Open. 2019;9(8):e025884. https://pubmed.ncbi.nlm.nih.gov/31399448/Annotation: Randomized controlled pilot of intravenous glutathione or placebo before and after primary angioplasty in 50 patients with ST-elevation myocardial infarction.
  19. 19.Peer-reviewedAlzahrani TF, Alotaibi SM, Alzahrani AA, Alzahrani AF, Alturki LE, Alshammari MM, Alharbi RA, Alanazi SI, Alshammari WZ, Algarni AS. Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review. Cureus. 2025;17(1):e78045. https://pubmed.ncbi.nlm.nih.gov/40013212/Annotation: The 2025 review statement that intravenous glutathione is associated with anaphylaxis and hepatotoxicity and lacks standardized dosing protocols.
  20. 20.RegulatoryFDA, Compounding Risk Alerts (index of alerts to health care professionals). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-risk-alerts
  21. 21.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm

Cite this page

ExaVeyra Sciences Editorial Team. Glutathione: Oral, IV and Topical Evidence. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/glutathione-oral-iv-topical-evidence. Accessed [date accessed].

ExaVeyra Exclusive Member Resources

For verified and approved practicesReserved for clinicians

Research Vault

Curated peer-reviewed literature for each catalog compound, with a printable two-minute brief, evidence at a glance and the papers to start with.

  • 266 peer-reviewed papers, each with its DOI or PubMed link
  • 8 research areas
  • 128 systematic reviews, meta-analyses and randomized trials
  • 18 compounds with a two-minute brief

Registration takes about two minutes. Access opens after NPI verification and a review by our team. No payment details.

Each brief opens with the strongest study designs first, then the newest.

Common questions

What did the randomized trials of oral glutathione in healthy adults report?
They disagree. Allen and Bradley found no change in oxidative stress biomarkers or glutathione status after four weeks in 40 volunteers. Richie and colleagues found increases in blood glutathione at both doses over six months in 54 adults, in most cases dose and time dependent, with levels returning to baseline one month after stopping. A later systematic review described the oral route as questionable because of limited absorption and bioavailability.
Is there a controlled trial of topical glutathione?
One. Watanabe and colleagues ran a randomized, double-blind split-face trial of an oxidized glutathione lotion against placebo in 30 healthy women for ten weeks and reported a lower melanin index on the treated side with no marked adverse effects. Three of the four authors were affiliated with the company that supplied the ingredient, and the 2019 systematic review called the overall skin evidence inconclusive.
What controlled evidence exists for intravenous glutathione?
PubMed indexes randomized, placebo-controlled intravenous trials in vascular, cardiac and neurological settings, among them a 2009 pilot in 21 people with Parkinson disease that reported good tolerability and no significant difference on the rating scale used. The dermatology reviews describe the intravenous evidence for skin lightening as a single placebo-controlled study with a dubious design and apparently flawed analysis, and a 2025 review associated the route with anaphylaxis and hepatotoxicity.
What did FDA find in the glutathione endotoxin cases?
In 2019 FDA investigated seven patients at one clinic who reacted within minutes of an intravenous infusion of compounded L-glutathione, plus a second hospitalized patient; its laboratory found endotoxin in the bulk powder at up to five times the appropriate limit, and the powder was labeled as a dietary supplement. In August 2026 FDA reported at least 30 patients with fever, chills, shock and sepsis-like symptoms after intravenous glutathione compounded from one dietary supplement grade lot from a different distributor, with two Texas pharmacies recalling product. FDA named the compounding suppliers involved in both alerts.
Where does glutathione sit in the 503A bulks list process?
FDA's category document updated 14 May 2026 lists glutathione in category 1, the substances nominated with sufficient information and under evaluation, for which FDA does not intend to take action against a compounder that meets the conditions of its interim policy. It is not in category 2, and no final rule on it had issued as of 8 November 2026. The statute still requires that the bulk substance come from an FDA-registered manufacturer and be accompanied by a valid certificate of analysis.
What should a practice ask its pharmacy about compounded glutathione?
FDA's 2026 alert asked health care professionals to check with their compounders about the source of the glutathione used for their patients. The documents that answer that question are the identity of the bulk source and its upstream manufacturer, the certificate of analysis for each lot, confirmation that the material is manufactured for the intended route of administration rather than labeled as a dietary supplement ingredient, and the pharmacy's approach to endotoxin control for sterile injectables.

This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. These references report what trials, reviews, product labels and FDA communications state about compounds that a 503A pharmacy partner prepares, for professional education, and make no statement about the suitability of any product for any patient. Where this page discusses an FDA-approved product, the approved labeling governs and nothing here modifies it. Compounded preparations are a separate product class: they are not FDA-approved finished drug products, they are prepared under section 503A of the Federal Food, Drug, and Cosmetic Act against a patient-specific prescription, and they are prescription products supplied to licensed practitioners only. Cosmetic ingredients discussed here are described within the cosmetic regulatory frame and are not drugs. The prescribing decision rests with the licensed practitioner. Read the full notice

Reference only. Not legal or medical advice.

The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Read the full notice